Anti R-IL2 + Cyclosporine then Everolimus — Competitive Intelligence Brief

Anti R-IL2 + Cyclosporine then Everolimus (Anti R-IL2 + Cyclosporine then Everolimus) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive combination therapy. Area: Immunology / Transplantation.

phase 3 Immunosuppressive combination therapy IL-2 receptor, calcineurin, mTOR Immunology / Transplantation Small molecule

Target snapshot

Anti R-IL2 + Cyclosporine then Everolimus (Anti R-IL2 + Cyclosporine then Everolimus) — University Hospital, Brest. This combination therapy sequentially suppresses T-cell activation via anti-IL-2 receptor blockade and calcineurin inhibition, followed by mTOR inhibition to prevent allograft rejection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anti R-IL2 + Cyclosporine then Everolimus TARGET	Anti R-IL2 + Cyclosporine then Everolimus	University Hospital, Brest	phase 3	Immunosuppressive combination therapy	IL-2 receptor, calcineurin, mTOR
ATG+mycophénolate mofétil+tacrolimus	ATG+mycophénolate mofétil+tacrolimus	University Hospital, Toulouse	marketed	Immunosuppressive combination therapy	T lymphocytes (ATG); IMPDH (mycophenolate mofetil); calcineurin (tacrolimus)
sirolimus, mycophenolat mofetil, fluvastatin	sirolimus, mycophenolat mofetil, fluvastatin	University Hospital Schleswig-Holstein	marketed	Immunosuppressive combination therapy with statin	mTOR, IMPDH, HMG-CoA reductase
Everolimus+Tacrolimus+Prednisone	Everolimus+Tacrolimus+Prednisone	Fundação Pró Rim	marketed	Immunosuppressive combination therapy	mTOR (everolimus), calcineurin (tacrolimus), glucocorticoid receptor (prednisone)
CsA+Rapamune+CS	CsA+Rapamune+CS	Pfizer	marketed	Immunosuppressive combination therapy	Calcineurin, mTOR, glucocorticoid receptor
tacrolimus OD, mycophenolic acid, prednisolone	tacrolimus OD, mycophenolic acid, prednisolone	University Medical Center Groningen	marketed	Immunosuppressive combination therapy	Calcineurin (tacrolimus); IMPDH (mycophenolic acid); glucocorticoid receptor (prednisolone)
Basiliximab, Tacrolimus, MMF	Basiliximab, Tacrolimus, MMF	University Hospital Freiburg	marketed	Immunosuppressive combination therapy	IL-2 receptor (basiliximab); calcineurin (tacrolimus); IMPDH (MMF)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive combination therapy class)

1. University Hospital, Brest · 2 drugs in this class
2. Pfizer · 2 drugs in this class
3. Fundação Pró Rim · 2 drugs in this class
4. Haukeland University Hospital · 1 drug in this class
5. Imperial College Healthcare NHS Trust · 1 drug in this class
6. Jinnah Postgraduate Medical Centre · 1 drug in this class
7. Novartis · 1 drug in this class
8. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. Swiss Cancer Institute · 1 drug in this class
10. University Hospital Freiburg · 1 drug in this class